Nieuws en video's - Aandelen - Pagina 2

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting PR Newswire GERMANTOWN, Md., April 24, 2024 GERMANTOWN, Md. , April 24, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical...

G-SHOCK INTRODUCES NEW DIGITAL BASIC STEP TRACKER SERIES PR Newswire DOVER, N.J., April 24, 2024 A Blend of Performance and Style Formulated In brand new Thin G-SHOCK case DOVER, N.J. , April 24, 2024 /PRNewswire/ -- Today, Casio America, Inc. proudly unveils its latest design innovation with sensor technology – the all-new Digital Basic GDB500 series . This groundbreaking series seamlessly combines sleek compact design with essential functionalities, including a step tracker and Bluetooth,...

EQS-Ad-hoc: Cherry SE / Schlagwort(e): Sonstiges Cherry SE: Cherry SE nimmt für 2023 bilanzielle Wertberichtigung von Vermögenswerten vor; keine Auswirkungen auf vorläufiges bereinigtes EBITDA und die Cashflow-Position 2023 24.04.2024 / 16:17 CET/CEST Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014, übermittelt durch EQS News - ein Service der EQS Group AG. Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich....

EQS-Ad-hoc: Cherry SE / Key word(s): Miscellaneous Cherry SE: Cherry SE recognizes asset impairment for 2023; no impact on preliminary adjusted 2023 EBITDA and cash flow position as well as the forecast for the 2024 financial year 24-Apr-2024 / 16:17 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. PUBLICATION OF AN...

Reference is made to the announcement of Fly Play hf. (“PLAY” or the “Company”) on April 11, 2024, regarding the results of a funding round. In a meeting held today, the Company’s Board of Directors decided to exercise the authority granted by the AGM to increase the Company’s share capital by issuing new shares by up to 1,200,000,000 shares in nominal value. As previously announced, the total amount of the authorization will not be used. The Company's Board of Directors decided at a...

Nature's Sunshine's Impact Report Highlights Achievements and Continued Commitment Toward Sustainability PR Newswire LEHI, Utah, April 24, 2024 LEHI, Utah , April 24, 2024 /PRNewswire/ -- Nature's Sunshine Products (Nasdaq: NATR), a leading natural health and wellness company of premium-quality herbal and nutritional products, today released its 2023 Comprehensive Impact Report . The report showcases Nature's Sunshine's advancements over the past 12 months, demonstrating its ongoing commitment...

NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM ( NCT04382664 ), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. INITIUM is an Ultimovacs-sponsored randomized, comparative, multicenter Phase II trial...

Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting PR Newswire SHANGHAI, April 24, 2024 Topline results from Dizal's global pivotal phase II WU-KONG1 Part B study of sunvozertinib will be showcased in a featured oral presentation at the conference. SHANGHAI , April 24, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to...

CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31-June 4, 2024. The data will include first results from the dose escalation cohort of CLN-619...

Vantage Foundation apoya las actividades educativas de la Oficina Regional de la UNESCO PR Newswire SINGAPUR, 24 de abril de 2024 - Vantage Foundation apoya las actividades educativas de la Oficina Regional de la UNESCO para Asia Meridional en Nueva Delhi (La India). SINGAPUR , 24 de abril de 2024 /PRNewswire/ -- El imperativo mundial de mejorar el acceso a la educación y su calidad sigue siendo primordial. A este respecto, la organización benéfica independiente Vantage Foundation señala que...

GRAINGER INCREASES QUARTERLY DIVIDEND BY 10%; REFRESHES SHARE REPURCHASE AUTHORIZATION PR Newswire CHICAGO, April 24, 2024 CHICAGO , April 24, 2024 /PRNewswire/ -- W.W. Grainger, Inc. (NYSE: GWW) announced today that its board of directors approved a quarterly cash dividend of $2.05 per share, an increase of 10% from the most recent company dividend. The dividend is payable on June 1, 2024 , to shareholders of record on May 13, 2024 . In addition, the board approved the repurchase of up to 5...

Greensboro, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Volvo Trucks North America has announced a significant advancement in its sustainability efforts by fueling newly assembled trucks with Hydrotreated Vegetable Oil (HVO), a renewable fuel, as they depart from the Volvo Trucks New River Valley Assembly Operations (NRV) in Dublin, Virginia. All Volvo trucks for the North American market are produced at the NRV plant, including the all-new Volvo VNL that will begin production later this summer....

Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic solid tumors WATERTOWN, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that an abstract...

Oral presentation of MDNA11’s Phase 1/2 ABILITY-1 Study will feature new and updated clinical data Updated bizaxofusp survival results from the Phase 2b recurrent glioblastoma trial versus propensity matched external control arm will also be presented as a poster TORONTO and HOUSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines,...

IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study PR Newswire SOUTH SAN FRANCISCO, Calif., April 24, 2024 Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024 , at 9:51 AM CDT The abstract summary will be available on Thursday, May 23, 2024 at ~5:00pm ET SOUTH SAN FRANCISCO, Calif. , April 24, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company...

Duke Energy's annual Impact Report shares progress toward a cleaner tomorrow that includes affordability and reliability PR Newswire CHARLOTTE, N.C., April 24, 2024 Carbon emissions from electric generation are down 48% from 2005 levels Since 2022, helped customers access nearly $377 million in financial support CHARLOTTE, N.C. , April 24, 2024 /PRNewswire/ -- Duke Energy (NYSE: DUK) today released its 2023 Impact Report , its 18th annual accounting of its progress toward its sustainable...

EQS-News: FCR Immobilien AG / Schlagwort(e): Anleihe FCR Immobilien AG: Fristgerechte Rückzahlung 5,25 %-Anleihe 2019/2024 24.04.2024 / 16:01 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. FCR Immobilien AG: Fristgerechte Rückzahlung 5,25 %-Anleihe 2019/2024 Pullach im Isartal, 24.04.2024: Die FCR Immobilien AG (“FCR”, ISIN DE000A1YC913) hat mit heutigem Tag den Gesamtbetrag der 5,25 %-Anleihe (WKN: A2TSB1) an das Bankhaus Gebr. Martin AG, vorzeitig...

BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL. The presentations will highlight the Company’s Phase 1 trials of its lead interleukin 2...

Emittent / Herausgeber: XTPL S.A. / Schlagwort(e): Sonstiges XTPL baut industriellen Prototyp eines Geräts zusammen mit führendem chinesischen Hersteller von Maschinen für die Flachbildschirm-Branche 24.04.2024 / 16:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. XTPL führt derzeit den fünften Verkauf eines Moduls für industrielle Umsetzung durch. Beim Endkunden handelt es sich um einen führenden chinesischen Hersteller von Maschinen für die...

Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be presented during oral abstract session (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 24 April 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating...